Gaza Famine Risk Grows as UN Warns Time Running Out for Help
Food consumption and nutrition measures reached their worst levels since the conflict began, the World Food Programme and Unicef said in a report. That means two out of three official famine thresholds have been breached.
Pressure is mounting on Western governments to push Israeli Prime Minister Benjamin Netanyahu to step up efforts to address the crisis as worries of massive starvation grow. Israel started restricting fresh aid shipments into the territory in March when it resumed its military campaign, and while it established a new system of supply distribution, that has been hit by problems.
Israel over the weekend increased aid distribution, but German Chancellor Friedrich Merz and US President Donald Trump have called for more supplies to reach those at risk of starvation.
Trump, a staunch defender of Israel, this week said he did not agree with Netanyahu's assertion that there is no starvation in Gaza and floated setting up 'food centers' to alleviate the situation in the territory.
'Whether they talk starvation or not, those are kids that are starving,' Trump told reporters on Tuesday. He added that Israel wanted to oversee the proposed food centers.
'They want to preside over the food centers to make sure the distribution is proper,' he said.
'The unbearable suffering of the people of Gaza is already clear for the world to see,' WFP Executive Director Cindy McCain said in the report. 'Waiting for official confirmation of famine to provide life-saving food aid they desperately need is unconscionable.'
Food consumption in Gaza has plunged since May, with 39% of people now going days without eating, the report from the agencies showed. More than 500,000 people, or almost a quarter of the population, are enduring famine-like conditions, and acute malnutrition has risen at an unprecedented rate.
Acute malnutrition and reports of starvation-related deaths — the third core famine indicator — are increasingly common. However, collecting robust data in Gaza is very difficult as health systems are collapsing, according to the report.
'We need to flood Gaza with large-scale food aid, immediately and without obstruction, and keep it flowing each and every day to prevent mass starvation,' McCain said. 'The longer we wait to act, the higher the death toll will rise.'
--With assistance from Skylar Woodhouse and Meghashyam Mali.
(Updates to add Trump remarks in starting in fifth paragraph.)
More stories like this are available on bloomberg.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
3 hours ago
- Time of India
US health research faces disruption as Trump administration pauses NIH grants, then restores them
US health research disrupted as Trump administration halts NIH funding temporarily The Trump administration temporarily halted billions of dollars in research funding from the National Institutes of Health (NIH), affecting scientific projects across the United States. The funds were later restored on the same day following intervention from senior White House officials, according to multiple federal sources and internal emails reviewed by The Washington Post and The Wall Street Journal. The pause stemmed from a budgetary directive issued by the Office of Management and Budget (OMB), which included a footnote limiting how the NIH could use its congressionally approved funding. The directive initially restricted the NIH to spend its budget solely on salaries and operating expenses, preventing it from issuing or renewing research grants. Budget footnote triggers temporary funding freeze According to an email obtained by The Washington Post, Neil Shapiro, associate director for budget at the NIH, informed staff that the OMB had given the agency its "full-year apportionment" but included a footnote that narrowed the scope of allowable expenditures. The document stated that funding for the rest of the fiscal year could only be allocated to "personnel compensation and benefits," halting financial support to external scientific researchers. As reported by The Wall Street Journal, this pause in funding impacted billions of dollars used to support research on major health issues such as cancer and diabetes. Most NIH-funded research is conducted by external scientists working at universities and laboratories across the country. Funding restored after White House intervention The temporary freeze was reversed later in the day, following intervention from senior officials within the Trump administration. People familiar with the matter told The Wall Street Journal that the original restriction was withdrawn and the funding was allowed to proceed. Although no official explanation was provided publicly by the White House at the time of the reversal, federal officials confirmed that NIH's research grants could resume as planned. Widespread impact on US research institutions The funding pause caused concern within the US scientific community, particularly because the NIH distributes the majority of its budget—amounting to tens of billions of dollars annually—to external researchers. These grants are crucial for advancing research into pressing public health challenges. NIH officials have not commented further on whether similar restrictions may be applied again. The agency continues to operate under guidance from the OMB, which oversees the allocation of federal spending across US agencies. TOI Education is on WhatsApp now. Follow us here . Ready to navigate global policies? Secure your overseas future. Get expert guidance now!
Time of India
3 hours ago
- Time of India
Siemens Healthineers expects up to $580 million tariff impact in 2026
Munich: Siemens Healthineers expects U.S. tariffs to have an impact of up to 500 million euros ($578 million) on 2026 results, its finance chief said on Wednesday, after the European Union and U.S. reached a framework trade agreement on Sunday. The German medical technology company estimates a 400-500 million euro hit in the "most realistic case" for the financial year starting in October, CFO Jochen Schmitz told journalists. He flagged a 200-250 million euro net impact from import duties on the current year. In May, the company had said it expected a 300 million euro hit in the second half of 2025. Its Dutch med-tech peer Philips also slashed its estimated tariff impact for this year on Tuesday. The EU-U.S. deal sets out a 15% import tariff on most EU goods from next month, lower than the 30% U.S. President Donald Trump had threatened to apply earlier in July. With 10% tariffs having already been in place, Schmitz said Siemens Healthineers took a 100 million euro hit in the third quarter, the results of which it reported on Wednesday. Over the medium term, Schmitz said he believed the company would be able to "manage away" all tariff effects. "That will be a combination partly of pricing, but also value-add structure changes under certain circumstances," he said. However, he added that it was too early to make structural decisions as many aspects of the tariff deal were still unclear. Siemens Healthineers also cited the tariff deal when slightly raising its full-year outlook. It expects annual comparable revenue growth of 5.5% to 6%, after previously guiding for 5-6%, and adjusted basic earnings of 2.30-2.45 euros per share, versus 2.20-2.50 euros expected in May. Its revenue was 5.66 billion euros in the third quarter, slightly above analysts' consensus. The company's shares were up 1.6% in Frankfurt as of 0835 GMT.
Mint
5 hours ago
- Mint
Who is Vinay Prasad? US FDA's top regulator exits agency after controversy over Sarepta gene therapy
Dr. Vinay Prasad, a top regulator at the US Food and Drug Administration, has resigned in less than three months in the job following a controversy over the handling of Sarepta Therapeutics Inc.'s gene therapy. 'Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family,' a report by CNN quoted a spokesperson for the US Department of Health and Human Services. In May, Prasad, a hematologist and oncologist was appointed head of the FDA's Centre for Biologics Evaluation and Research, granting him authority over vaccines and biological medicines. Subsequently, he was also appointed the FDA's chief medical and scientific officer. Similar to several Trump administration health appointees, Prasad had been a vocal critic of the government's response and vaccine policies during the COVID-19 pandemic. The report, citing people aware of the development, said Prasad resigned amid pressure from the White House. Additionally, Laura Loomer, a right-wing activist known to have close ties with Donald Trump, consistently criticised Prasad. She publicly criticised him for days on her website and social media, calling him a 'progressive leftist saboteur' who was 'undermining President Trump's FDA.' Loomer called out Prasad's previous social media posts and podcast episodes, where she claimed that he supported liberal politicians and expressed 'disdain' for Trump. However, FDA Commissioner Dr. Marty Makary defended Prasad just days ago. In an interview with Politico, Makary said Prasad is an 'impeccable scientist … one of the greatest scientific minds of our generation.' 'We thank him for his service and the many important reforms he was able to achieve in his time at FDA,' the spokesperson for HHS said. Prasad took on his role at the FDA following years of outspoken criticism of certain drug approvals by the agency. Notably, he condemned the approval of Sarepta's Duchenne muscular dystrophy drug, Elevidys, asserting that there was insufficient evidence to demonstrate it effectively slowed or reversed symptoms of this rare and deadly genetic condition. This month, the FDA asked Sarepta to stop shipments of the drug after a reported death of a young patient in Brazil. Just one day before Prasad's departure, the agency unexpectedly reversed its decision and allowed Sarepta to continue shipments for certain patients. Prasad faced criticism from former officials and vaccine experts after May's internal memos showed he overruled FDA scientists on two new Covid-19 vaccine versions. The then-CDER director criticised the broad use of these vaccines; ultimately, the FDA approved them for older and immunocompromised individuals but did not recommend them for younger Americans without underlying health conditions.
